Navigation Links
Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
Date:3/20/2013

WILMINGTON, Del., March 20, 2013 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the leading biobutanol technology company, announced today it would appeal the Court's claim construction and decisions on certain motions before the Court in Butamax's litigation against Gevo.

Paul Beckwith , Butamax Chief Executive Officer, stated, "Butamax has decided to appeal this case immediately.  Butamax strongly disagrees with the Court's claim construction.  We do not believe it is consistent with either the patent, rules for patent claim construction or statements made by the Federal Circuit.  We have therefore decided to appeal immediately to resolve this matter before going to trial.  We are confident the Federal Circuit will determine this matter in our favor."

The Court made no overall determination on literal infringement and denied Gevo's motions of invalidity on all but two of 37 patent claims being asserted by Butamax against Gevo.  However, despite previous statements from the Federal Circuit, the Court chose a very narrow claim construction for the KARI enzyme element of the claims.  This narrow interpretation, in Butamax's view, is in error as a matter of law and therefore Butamax is taking this claim construction immediately back to the Federal Circuit for appeal.

Beckwith continues, "This is still an early stage in what is likely to be a long and complicated litigation, involving many patents that will take several years for the courts to resolve.   Butamax is currently enforcing six other patents against Gevo and will vigorously continue to do so while this case is appealed."

Butamax remains strongly committed to near term commercialization of its biobutanol technology.  Butamax will continue its strategy of bringing advanced biofuels to the consumer and providing a real solution to the blendwall.

About Butamax 

Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:  
Mark Buse  202-679-5576 
Mark.Buse@butamax.com

 


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
4. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
5. USPTO Grants Butamax a Further KARI Enzyme Patent
6. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
7. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
10. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2020)... ... May 20, 2020 , ... ... who will serve as the company’s executive vice president of product engineering and ... is disrupting the medical imaging space, bringing more than 24 years of technology ...
(Date:5/15/2020)... ... 14, 2020 , ... Children with defective heart valves often ... becoming adults. The reason: there are no heart valve prosthetics designed to grow ... of Defense has awarded Draper, Boston Children’s Hospital and Seattle Children’s Research Institute ...
(Date:5/15/2020)... ... 15, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel ... Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he ... Brian Miller and Sentien’s management team. , Mr. Ganz has more than ...
(Date:5/14/2020)... ... May 12, 2020 , ... NanoString ... bringing together thousands of industry leaders, clinicians, research scientists, medical professionals and academics ... Carl June, MD, Director of the Center for Cellular Immunotherapies at the Perelman ...
Breaking Biology Technology:
(Date:6/2/2020)... (PRWEB) , ... June 02, ... ... the world’s leading barcode and RFID labeling software developer and solutions provider, ... TEKLYNX CENTRAL , improved labeling accuracy and compliance by 100%, resulting in ...
(Date:5/28/2020)... , ... May 28, 2020 , ... ... that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) ... Meeting which will take place virtually on May 29th, 2020. Dr. Benedito Carneiro, ...
(Date:5/21/2020)... SOMERSET, N.J. (PRWEB) , ... May 20, 2020 ... ... technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and ... Catalent Cell & Gene Therapy, will be presenting at the ISCT 2020 Paris ...
Breaking Biology News(10 mins):